Carregant...
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation
AIMS: Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective ‘extended RAS’ analyses have been performed on clinical trial material. Despite this, are...
Guardat en:
| Publicat a: | J Clin Pathol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5256378/ https://ncbi.nlm.nih.gov/pubmed/27681846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jclinpath-2016-203822 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|